Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and disease-related immune dysfunction, announces that Chairman Dr. Hans Keirstead will speak at the prestigious BIO International Convention in San Diego. This collaborative event hosts over 18,000 industry leaders and is renowned for fostering global partnerships and innovation. With a remarkable track record of founding and successfully exiting multiple biotech firms, Dr. Keirstead is a true biomedical visionary fit for the BIO stage.

Our metabolic health declines with age and commonly manifests as obesity, muscle atrophy, and limited physical function. There are currently no FDA-approved interventions to combat weight gain without losing muscle mass, demonstrating an unmet clinical need. Enter IMMUNA.

In his presentation, Dr. Keirstead plans to discuss the transformative results of Immunis’ novel, investigational secretome, IMMUNA. The preclinical data published in Aging Cell show that IMMUNA increases whole-body lean mass and reduces fat mass, while increasing muscle fiber area. The secretome also improves the physiology of aged mouse models of muscle atrophy by enhancing grip strength, increasing energy expenditure and boosting physical activity. Additionally, the most recent milestones of Immunis’ ongoing Phase 1/2a clinical trial highlights the potential benefits of IMMUNA in reversing muscle atrophy in aged humans.

This marks Dr. Keirstead’s second consecutive year as a presenter at BIO on behalf of Immunis. The company is proud to be represented by an incredibly talented individual whose dedication to advancing treatments that address critical areas in healthcare. We look forward to the valuable discussions and collaborations that this occasion has to offer.

About BIO International Convention

The BIO International Convention represents the largest global event for biotech, offering networking, partnership opportunities, and insights from key industry leaders. For more information, please visit: https://www.bio.org/events/bio-international-convention

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com